Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer

Inclusion Criteria: * PHASE I ELIGIBILITY CRITERIA * Patients must have histological or cytological confirmation of renal cell carcinoma (clear cell, papillary, chromophobe, or sarcomatoid) not curable by standard approaches; tumor must be measurable by Response Evaluation Criteria In Solid Tumors (RECIST) criteria; nephrectomy prior to enrollment is not required * Patients may not have had prior therapy with inhibitors of the mitogen-activated protein (MAP) kinase pathway or inhibitors of VEGF and/or its receptor signaling (VEGFR2) * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Life expectancy of greater than 3 months * Hemoglobin (Hgb) \>= 9.0gm/dl (transfusions allowed prior to enrollment) * White Blood Count \>= 3,000/mm\^3 * Absolute Granulocyte Count \>= 1,200/mm\^3 * Platelet Count \>= 100,000/mm\^3 * Serum creatinine =\< 1.5 x upper limit of normal (ULN) or serum creatinine clearance (CrCl) \>= 40ml/min (neither drug is cleared by the kidney) * Total Bilirubin =\< 1.5 x ULN * Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =\< 2.5 x ULN * International normalized ratio (INR) =\< 1.5 and activated partial thromboplastin time (aPTT) that is not greater than 1.3 times the ULN * Urine Dipstick must show less then 1+ protein in urine or the patient will require 24 hour urine collection with total protein =\< 1000 mg/24 hour * Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier m…